When was Vogenx founded?

Vogenx was founded in 2020 and raised its 1st funding round 5 years after it was founded.

Where is Vogenx located?

Vogenx is headquartered in Raleigh, United States.

How many employees does Vogenx have?

As of Sep 30, 2026, the latest employee count at Vogenx is 10.

Is Vogenx a funded company?

Vogenx is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Dec 10, 2025.

When was the latest funding round of Vogenx?

Vogenx's latest funding was a $***** Conventional Debt round on Dec 10, 2025, with participation from 0 investor. Its primary sector is Metabolic Diseases. In United States, the Metabolic Diseases sector has seen $1.36B in funding in 2026 to date.

Where does Vogenx rank among its competitors?

Vogenx ranks 106th amongst 436 active competitors, of which 163 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Adocia, which secured $11.7M in Dec, 2025.

Who are the top competitors of Vogenx?

Vogenx's top competitors include BioMarin Pharmaceutical, Rhythm Pharmaceuticals and MannKind Corp. Among them, Adocia secured the most recent funding round in December, 2025.

Vogenx - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of serious metabolic and gastrointestinal diseases. The company's product line include Mizagliflozin which is a small molecule inhibitor of sodium glucose transporter 1 (SGLT1) which act on intestinal lumen for the treatment of post bariatric hypoglycemia.

Website: vogenx.com
Email ID: *****@vogenx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Raleigh, United States

Stage

Public

Latest Funding Round

Conventional Debt, Dec 10, 2025, $*****

Ranked

106^th among 436 active competitors

Employee Count

10 as on Sep 30, 2026

Similar Companies

BioMarin Pharmaceutical & 408 more

Exit Details

Public

View Vogenx's full profile

Vogenx got listed on Aug 12, 2026.

Click here to take a look at Vogenx's IPO in detail

Vogenx has raised funding over 1 round.

Here is the list of recent funding rounds of Vogenx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 10, 2025	5163945	Conventional Debt	4399339	4910526	4762467	9397961

Access funding benchmarks and valuations. Sign up today!

View details of Vogenx's funding rounds and investors

Vogenx's employee count trend

Vogenx has 10 employees as of Sep 26. Here is Vogenx's employee count trend over the years:

Uncover Vogenx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vogenx include BioMarin Pharmaceutical, Rhythm Pharmaceuticals and MannKind Corp. Here is the list of Top 10 competitors of Vogenx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	73/100
2nd	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	72/100
3rd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	71/100
4th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, BioBrit & 7 others	69/100
5th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	65/100
6th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	67/100
7th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	67/100
8th	Assembly Biosciences 2005, New York City (United States), Public	Developing novel antivirals to treat serious viral diseases	$700K	Avoro Capital, Armistice Capital & 3 others	67/100
9th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	65/100
10th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Shire, Cathay Financial Holdings & 18 others	65/100
106th	Vogenx 2020, Raleigh (United States), Public	Developer of therapeutics for the treatment of serious metabolic and gastrointestinal diseases	-	-	46/100